Business Wire

CA-SYSDIG,-INC.

28.4.2021 13:02:11 CEST | Business Wire | Press release

Share
Sysdig Raises $188M at a Valuation of $1.19B to Secure Modern Cloud Applications

Sysdig, Inc., the secure DevOps leader, today announced a $188 million Series F funding round at a valuation of $1.19 billion. This round brings Sysdig ’s total funding to $394 million since inception. The financing was led by Premji Invest & Associates and Third Point Ventures, with participation from Accel, Bain Capital Ventures, DFJ Growth, Glynn Capital, Goldman Sachs, Insight Partners, and Next47. The company also announced that Robert Schwartz from Third Point Ventures, Sandesh Patnam from Premji Invest & Associates, and Enrique Salem from Bain Capital Ventures have joined its board of directors .

Blog from CEO Suresh Vasudevan: Our $188M funding round fuels our mission to help customers confidently run modern cloud applications

The Sysdig Secure DevOps Platform uniquely addresses the challenges of securing containers, Kubernetes, and public cloud infrastructure. Sysdig is trusted by hundreds of leading enterprises, including Worldpay by FIS, Yahoo Japan, IBM, and JW Player to confidently run modern cloud applications while managing security risks and meeting compliance requirements.

This round follows strong growth in 2020, a rapidly expanding customer base, a thriving open source community, and a massive growth opportunity with containers and cloud.

Key Milestones:

  • New annual contract value (ACV) added during the second half of the 2021 fiscal year (FY21) was 2.3 times the amount added in the same period, the previous fiscal year,* reflecting increasing cloud adoption and momentum throughout 2020.
  • 450 enterprise customers, including dozens of large global enterprises, with an average annual recurring revenue (ARR) of more than $500,000 across the top 50 purchasing customers.
  • Strong pattern of expansion by customers as demonstrated by an annual net revenue retention (NRR) of 140% at the end of FY21.
  • With nearly 24 million downloads, including 1.7 million in the last month, Falco adoption has increased 300% in the last year.
  • Sysdig significantly expanded the total addressable market (TAM) beyond container and Kubernetes security to include cloud security with the addition of continuous cloud security posture management (CSPM) in 2021. The served addressable market (SAM) also increased with the delivery of more than 50 significant features last year, including the first inline scanning for Fargate , zero trust network security , and cloud-scale Prometheus monitoring .

*The 2021 fiscal year ran from February 2020 - January 2021.

In November 2020, Gartner increased its 2021 public cloud forecast to total $304.9 billion, up from $257.5 billion in 2020. [1] Modern applications are increasingly built as highly distributed microservices, leveraging containers and Kubernetes, and a vast array of services on public cloud platforms. While this shift accelerates innovation, it presents unique challenges that legacy security tools, built with a proprietary, firewall mindset, are unable to address. To manage risk without slowing down application delivery, companies need a security stack:

  • Architected for secure DevOps.
  • Built on open source to accelerate innovation and drive standardization.
  • Delivered as SaaS for simplicity and scale.
  • That provides deep visibility across containers and cloud.

Run Containers, Kubernetes, and Cloud Applications Confidently with Secure DevOps

The Sysdig Secure DevOps Platform provides security and visibility to confidently run containers, Kubernetes, and cloud. Customers rely on the platform to secure the software build pipeline, detect and respond to runtime threats, monitor service health, and continuously validate cloud security posture and compliance.

Sysdig’s SaaS deployment model and curated, out-of-the-box workflows enable companies to reduce security risk while also improving operational efficiency by 25-50 percent. With functionality that spans cloud security posture, cloud workload protection platform, and container monitoring markets, 85 percent of new customers purchase the platform solution, replacing three point solutions.

Sysdig was founded as an open source company and the Sysdig Secure DevOps Platform was built on an open source foundation to address the security challenges of modern cloud applications. Open source sysdig and Falco are projects that were created by Sysdig to leverage deep visibility as a foundation for security, and they have become standards for container and cloud threat detection and incident response. Falco, which was contributed to the Cloud Native Computing Foundation (CNCF) in 2018, is now an incubating-hosted level project. Last year, Sysdig announced full compatibility and scalability for Prometheus, the CNCF project second in popularity to Kubernetes. Sysdig’s CSPM capability incorporates the popular Cloud Custodian, a CNCF project for static configuration checks.

Focus of this Investment

This new round of investment will enable Sysdig to invest in continued innovation in its open source foundation as well as in its secure DevOps platform, and grow research and development teams in Raleigh, Spain, Italy, Belgrade, and San Francisco. The funding will drive expansion of sales and marketing in existing markets within the United States, Europe, Japan, and Australia, as well as entry into newer markets in the Asia-Pacific region. A key emphasis will be on continuing to build ecosystem and channel partnerships and local SaaS regions around the globe.

Quotes

Enrique Salem, Partner, Bain Capital Ventures: “The current security stack based on a firewall mentality and promoted by incumbents is irrelevant in the cloud. Sysdig takes a secure DevOps approach, allowing teams to ship cloud apps faster while managing security risk. They built on an open source security stack, which we see accelerates innovation and adoption.”

Sandesh Patnam, US Managing Partner, Premji Invest & Associates: “The cloud is driving a transformative shift in the way applications are developed and secured. This levels the playing field for young, innovative companies to emerge as leaders in this new, exciting category. We are extremely deliberate in our investments and expect Sysdig will not only have a successful IPO, but deliver strong long-term returns in the public market.”

Robert Schwartz, Managing Partner, Third Point Ventures: “Sysdig took several steps early on that differentiated it from other solutions, including taking an open source approach to container and Kubernetes security well before others jumped on the bandwagon. This has paid off tremendously for them. Sysdig has a marquee customer base and proven its ability to scale. We’re excited to be joining the Sysdig team and can’t wait to help them accelerate from here.”

Ping Li, Partner, Accel: “Accel partnered with Sysdig early on, with a belief that a DevSecOps stack, based on open source, deployed as SaaS is a winning formula. Today, they are the clear leader in runtime security for containers and cloud.”

Suresh Vasudevan, Chief Executive Officer, Sysdig: “Sysdig was founded as an open source company and architected for secure DevOps. In contrast, Palo Alto was founded as a proprietary firewall company, and that mindset slows app delivery in the cloud. The leading security stack for cloud delivered apps will be built on open source with a secure DevOps approach that delivers deep visibility into containers and cloud.”

[1] Gartner, Gartner Forecasts Worldwide Public Cloud End-User Spending to Grow 18% in 2021, Katie Costello and Meghan Rimol, 17 November 2020

About Sysdig

Sysdig is driving the secure DevOps movement, empowering organizations to confidently secure containers, Kubernetes, and cloud. With Sysdig, teams secure the build, detect and respond to threats, continuously validate cloud posture and compliance, and monitor performance. Sysdig is a SaaS platform, built on an open source stack that includes Falco and sysdig OSS, the open standards for runtime threat detection and response. Hundreds of companies rely on Sysdig for container and cloud security and visibility. Learn more at www.sysdig.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye